SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Creative poster collage of two business partners having deal financial payment giving money banknote isolated on beige color background.
Manufacturing
Samsung Biologics inks $262M manufacturing deal with European pharma company
The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.
September 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Businessman leader leads a team through a crisis. on a paper boat at sea with dangerous sharks A symbol of overcoming obstacles and challenges. isometric vector illustration.
C-suite
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
September 11, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Conceptual origami paper plane pulling business finance growth chart line flying upwards on blue sky background.
Manufacturing
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion of its portfolio.
September 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis - 3d illustration
Manufacturing
Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.
September 8, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business and financial crisis vector concept with businessman levitating and trying do not fall to abyss. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration
Mergers & acquisitions
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
September 2, 2026
 · 
5 min read
 · 
Nick Paul Taylor
A closed sign hanging on the door of a business
Manufacturing
Vitruvias vanishes amid thyroid tablets recall over potential ‘superpotency’ concerns
Vitruvias Therapeutics has “ceased operations” after voluntarily recalling a batch recall of generic thyroid tablets due to possible superpotency that could cause a range of adverse events.
August 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Manufacturing
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
August 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3d rendering of Radiopharmaceuticals, these are radioactive medications or radioisotopes. These medications can be delivered orally in pill form.
Manufacturing
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.
August 25, 2026
 · 
4 min read
 · 
Nick Paul Taylor
GLP-1 weighloss pills - five pills in a row on blue background with harsh lighting - orthographic perspective
Weight loss
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
August 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Rare disease ribbon with cut-outs of people
Rare diseases
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Checklist, Icon, Clipboard, List, Questionnaire
Gene therapy
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September.
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
Cancer
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.
August 19, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Obesity
Enveda’s exercise-simulating obesity tablet clears early clinical test
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
August 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Sleeping girl in the pill bottles. concept of pills, good sleep, Insomnia, exhausted and frustrated
Neuroscience
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
August 19, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Business negotiation, deal making or acquisition, merger vector concept. Two men shaking hands. Minimal design. Eps10 illustration
Manufacturing
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
August 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor